HVA/DOPAC Ratio

The HVA/DOPAC ratio compares urinary homovanillic acid (HVA) with urinary 3,4-dihydroxyphenylacetic acid (DOPAC). Both are products of dopamine breakdown. This test uses LC-MS to measure the compounds, then reports their ratio. The result describes their relative amounts in your sample; it doesn't establish how quickly your body clears dopamine.

The urinary ratio remains a research-stage marker. There are no generally accepted clinical cutpoints or proven treatment targets. Its value for predicting disease, explaining symptoms, or guiding treatment hasn't been established. Evidence about either compound individually, or about the same compounds in spinal fluid or brain tissue, doesn't validate this urine measurement.

How Dopamine Gets Broken Down

Dopamine is a chemical messenger used in the brain and elsewhere in the body. Enzymes are proteins that carry out chemical reactions. Several enzymes participate in dopamine breakdown, and there is more than one route to HVA.

In one route, two successive reactions involving MAO and ALDH convert dopamine into DOPAC. COMT then converts DOPAC into HVA. COMT can also act on dopamine first, producing 3-methoxytyramine, which is converted into HVA through further reactions.

This makes the ratio biologically interesting, but it prevents a simple reading of it as the percentage of dopamine breakdown that's complete. HVA can arrive through a route that bypasses DOPAC, and the amounts excreted also depend on production, further chemical processing, and kidney handling.

Where the Urine Signal Comes From

Urine combines contributions from processes throughout the body. Studies sampling blood across different organs show substantial HVA production outside the brain. Separate human urine studies have found that kidney disease changes the excretion of both HVA and DOPAC. Neither finding establishes what fraction of your urinary ratio comes from the brain.

Research on the source of urinary dopamine itself also can't supply that fraction. Dopamine, HVA, and DOPAC are different molecules with different production and clearance patterns. A percentage describing where urinary dopamine originates shouldn't be applied to its breakdown products.

What a Higher or Lower Ratio Shows

• A higher ratio: more measured HVA relative to measured DOPAC. This can result from HVA increasing, DOPAC decreasing, or both changing by different amounts.
• A lower ratio: less measured HVA relative to measured DOPAC. This can result from HVA decreasing, DOPAC increasing, or both changing by different amounts.

Neither direction has an established meaning of better or worse health. The individual measurements provide information that the ratio loses: both compounds could double while the ratio stays unchanged. A urinary ratio also hasn't been validated as a way to identify inherited COMT variants or measure COMT activity throughout your body.

Parkinson's Disease Research

Several human studies have examined these compounds in cerebrospinal fluid. This fluid surrounds the brain and spinal cord. In a study of 276 people with early Parkinson's disease or without the disease, researchers used LC-MS/MS and found lower concentrations of dopamine breakdown products in the Parkinson's groups. These were measurements in a different body fluid, not measurements of the urinary HVA/DOPAC ratio.

A later analysis included 95 people with early Parkinson's and 56 comparison participants. Among those with Parkinson's, lower starting spinal fluid DOPAC and HVA were associated with faster cognitive decline over six years. The analysis used the PPMI research cohort, which also contributed participants to the earlier study.

A separate study found a lower HVA/DOPAC ratio and evidence of altered COMT-related metabolism in postmortem olfactory bulb tissue from people with Parkinson's. The olfactory bulb processes information about smell. That study used brain tissue and electrochemical detection, so its findings can't establish how to interpret this LC-MS urine result.

These findings support continued research into dopamine metabolism in Parkinson's. They don't establish the urine ratio as a screening test for people with a family history, a measure of brain dopamine, or a predictor of cognitive decline.

Dopamine-Producing Tumors

Urinary HVA has an established clinical use that the HVA/DOPAC ratio doesn't share. HVA and VMA measurements help investigate and monitor neuroblastoma. This childhood cancer develops from immature nerve cells. VMA is a breakdown product of norepinephrine and epinephrine.

An expanded panel of eight urinary compounds detected more neuroblastoma cases than HVA and VMA alone in one study, but also produced more false-positive results. That panel didn't validate the HVA/DOPAC ratio.

Even established diagnostic markers don't necessarily make useful population screening tests. A controlled study that screened about 1.5 million children with urinary HVA and VMA found no reduction in neuroblastoma deaths and evidence of overdiagnosis. Screening identified some tumors that would likely have regressed or remained clinically silent.

For suspected pheochromocytoma or paraganglioma, recommended initial biochemical testing uses plasma free metanephrines or urinary fractionated metanephrines. These are different tests. An unusual HVA/DOPAC ratio alone doesn't establish a reason for a tumor investigation.

Gut and Stress Research

A study comparing 40 women with functional constipation and 40 women without it found about a quarter more urinary HVA in the constipation group. Functional constipation describes persistent constipation without an identified structural cause. The researchers used LC-MS/MS and examined HVA alongside a serotonin breakdown product. They didn't measure DOPAC or evaluate this ratio.

In another study of 100 workers, the group reporting greater stress had about 17% lower urinary HVA. Dopamine was also lower, while the routine laboratory measurements didn't differ significantly between groups. The study used LC-MS, but didn't measure DOPAC. These observations don't establish the HVA/DOPAC ratio as a stress test or show that changes in it track recovery.

Experiments with cultured gut bacteria have shown that some bacteria can convert DOPAC into another compound. That provides a possible mechanism for microbial effects on dopamine-related chemicals. It hasn't established the size or direction of an effect on the urinary HVA/DOPAC ratio in people.

When Results Can Be Misleading

• Medication effects: older urine studies using gas chromatography found large increases in HVA and DOPAC during levodopa treatment. A small entacapone trial found reduced urinary HVA, alongside changes in blood metabolites. These studies establish effects on individual compounds, but don't provide treatment targets or a reliable predicted change for this urine ratio.
• Kidney function: a human study using liquid chromatography found lower urinary HVA and DOPAC excretion in people with reduced kidney function. Changes in these compounds can therefore reflect processes beyond dopamine production.
• Free versus total compounds: some HVA and DOPAC molecules are chemically attached to other molecules before excretion. This is called conjugation. An older urine study using gas chromatography found different proportions of conjugated HVA and DOPAC, with substantial differences between people. Measuring only free compounds can produce a different ratio from measuring free and conjugated compounds together.
• LC-MS interference: other substances in urine can weaken or strengthen the instrument's signal. Sample preparation, calibration, and suitable internal standards help control this, but an LC-MS label alone doesn't establish the accuracy of a particular assay.
• Small denominator: when DOPAC is near the assay's measurement limit, a small measurement error can produce a large change in the calculated ratio. Both measurements must be reliable before the ratio can be interpreted.
• Urine dilution: dilution should cancel mathematically when both compounds are measured accurately in the same sample. Very dilute urine can still leave one or both concentrations too low for reliable measurement.

Published precision figures for an HVA-only assay or an HVA/VMA assay don't establish the precision of this ratio. Both components and the calculation need validation. Likewise, day-to-day variation reported for urine albumin, iodine, or other unrelated compounds can't be used to decide whether a change in HVA/DOPAC is meaningful.